Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Determining the influence of metformin treatment on mitochondrial calcium flux during aerobic exercise training of healthy, aging rats

Award Number: F32AG087622
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 06/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2025

Group Awards By:

View Award Description

Determining the influence of metformin treatment on mitochondrial calcium flux during aerobic exercise training of healthy, aging rats - Project Summary Metformin (MET), the most widely prescribed medication for treating type 2 diabetes, is increasingly recognized for its healthspan extension effects. If MET is to be an effective healthspan extending drug, it is critical to understand the effects of MET during periods of relative health and how it interacts with other healthspan-related interventions such as exercise. Studies that have examined the MET-exercise interaction overwhelmingly show that MET inhibits the positive effects of aerobic exercise training (AET), but the mechanisms behind this effect are still unknown. Our recent clinical trial also demonstrated that subjects with the highest mitochondrial complex 1 supported respiratory function and insulin sensitivity were the most negatively affected by MET treatment with an exercise intervention. The proposed study will determine if the detrimental effects of MET treatment on skeletal muscle adaptations to AET involves altered calcium handling. Calcium handling is imperative for mitochondrial function, adaptations to exercise, and muscle health during aging. This project is significant because it further defines the context-specificity of MET benefits on healthspan. We hypothesize that MET treatment will impede calcium flux into the mitochondria during exercise training in aging rats, inhibiting the positive adaptations to AET. To test this hypothesis, we will use a rat model with genetic selection for high intrinsic aerobic capacity (HCR) because they represent, by many outcomes, healthy human subjects. The Specific Aims are to: 1) Determine how MET treatment alters mitochondrial calcium flux during AET and 2) Determine if MET treatment during AET alters the turnover of calcium handling proteins and structures regulating calcium kinetics. We will assess in vivo cytosolic and mitochondrial calcium kinetics using 2-photon fluorescence microscopy. Changes to mitochondrial calcium flux and function of skeletal muscle with and without 12 weeks of AET and/or MET will be measured using an Oroboros O2K. To determine if MET changes adaptations to AET, we will develop a targeted mitochondrial proteomics panel to measure the quantity and turnover of mitochondrial and calcium-handling proteins. We will also use a novel optic clearing technique in combination with light sheet microscopy to establish changes to mitochondrial-associated membrane contacts (MAM) structure and location with and without MET. We expect that with MET treatment, animals will have a lower rate of mitochondrial calcium uptake coupled with lower respiration, and that this inhibition will be more prominent in the exercised animals. Additionally, we expect MET will negatively impact the mitochondrial proteome related to calcium flux and hinder improvements associated with MAM number and distance to calcium release units in response to exercise. Successful completion of these aims will allow us to uncover mechanisms that contribute to the inhibition of AET adaptations with MET treatment in aging animals. Key training aspects include novel bioenergetic, flux and proteomic assessments of calcium handling in mitochondria that are crucial for my development to an independent investigator focused on targeting mitochondria for muscle aging.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2027 ( Subtotal = -$2,165 )
2027	2025	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Aging Research	000	2	10/27/2026	NON-COMPETING CONTINUATION	-$2,165
														Subtotal = -$2,165

Issue Date FY: 2025 ( Subtotal = $50,690 )
2025	2025	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Aging Research	000	2	6/24/2025	NON-COMPETING CONTINUATION	$50,690
														Subtotal = $50,690

Issue Date FY: 2024 ( Subtotal = $74,284 )
2024	2024	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Aging Research	001	1	5/24/2024	NEW	$0
2024	2024	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Aging Research	000	1	5/24/2024	NEW	$74,284
														Subtotal = $74,284

Grand Total All Awards = $122,809

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Determining the influence of metformin treatment on mitochondrial calcium flux during aerobic exercise training of healthy, aging rats

Award Number: F32AG087622

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 06/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer